دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Reducing polymicrobial and enteric peritonitis: a gut response
Shiyu Lu, Muthana Al Sahlawi, Jeffrey Perl
doi : 10.1093/ndt/gfac326
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1061–1063
The need for a multi-disciplinary reflection about frailty and cognitive impairment in chronic kidney disease
Michele Farisco, Irene Zecchino, Giovambattista Capasso, the CONNECT Consortium
doi : 10.1093/ndt/gfac334
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1064–1066
Avacopan for ANCA-associated vasculitis – information for prescribers
Dominic McGovern, Rachel B Jones, Lisa C Willcocks, Rona M Smith, David R W Jayne, Andreas Kronbichler
doi : 10.1093/ndt/gfac330
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1067–1070
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
Jennifer S Lees, Benjamin M P Elyan, Sandra M Herrmann, Ninian N Lang, Robert J Jones, Patrick B Mark
doi : 10.1093/ndt/gfac011
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1071–1079
Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in the non-cancer population. Across various populations, CKD is associated with an elevated risk of cancer incidence and cancer death compared with people without CKD, although the risks are cancer site-specific.
The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance
Raymond Vanholder, John Agar, Marion Braks, Daniel Gallego, Karin G F Gerritsen, Mark Harber, Edita Noruisiene, Jitka Pancirova, Giorgina B Piccoli, Dimitrios Stamatialis, Fokko Wieringa
doi : 10.1093/ndt/gfac160
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1080–1088
The world faces a dramatic man-made ecologic disaster and healthcare is a crucial part of this problem. Compared with other therapeutic areas, nephrology care, and especially dialysis, creates an excessive burden via water consumption, greenhouse gas emission and waste production.
Renal denervation in patients with chronic kidney disease: current evidence and future perspectives
Roland E Schmieder
doi : 10.1093/ndt/gfac189
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1089–1096
Supported by several high-quality randomized controlled trials and registry analyses, catheter-based renal denervation is becoming an important adjunctive treatment modality for the safe and efficacious treatment of hypertension besides lifestyle modifications and antihypertensive medication.
The conundrum of the complex relationship between acute kidney injury and cardiac arrhythmias
Simonetta Genovesi, Giuseppe Regolisti, Alexandru Burlacu, Adrian Covic, Christian Combe, Sandip Mitra, Carlo Basile, The EuDial Working Group of ERA
doi : 10.1093/ndt/gfac210
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1097–1112
Acute kidney injury (AKI) is defined by a rapid increase in serum creatinine levels, reduced urine output or both. Death may occur in 16–49% of patients admitted to an intensive care unit with severe AKI.
The European Kidney Health Alliance (EKHA) and the Decade of the KidneyTM
Raymond Vanholder, Paul T Conway, Daniel Gallego, Eveline Scheres, Fokko Wieringa
doi : 10.1093/ndt/gfac211
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1113–1122
The European Kidney Health Alliance (EKHA) is an advocacy organization that defends the case of the kidney patients and the nephrological community at the level of the European Union (EU), and from there, top to bottom, also at the national level of the EU member states and the EU-associated countries
Steroid-sensitive nephrotic syndrome in children
Olivia Boyer, Agnes Trautmann, Dieter Haffner, Marina Vivarelli
doi : 10.1093/ndt/gfac314
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1123–1126
Towards a better understanding of arterial calcification disease progression in CKD: investigation of early pathological alterations
Geoffrey Van den Bergh, Britt Opdebeeck, Cédric Neutel, Pieter-Jan Guns, Guido De Meyer, Patrick D'Haese, Anja Verhulst
doi : 10.1093/ndt/gfac301
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1127–1138
Cardiovascular disease remains the leading cause of death in chronic kidney disease (CKD) patients, especially in those undergoing dialysis and kidney transplant surgery.
TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment
Mai M Abdelmageed, Eirini Kefaloyianni, Akshayakeerthi Arthanarisami, Yohei Komaru, Jeffrey J Atkinson, Andreas Herrlich
doi : 10.1093/ndt/gfac290
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1139–1150
Inflammation is a key driver of the transition of acute kidney injury to progressive fibrosis and chronic kidney disease (AKI-to-CKD transition). Blocking a-disintegrin-and-metalloprotease-17 (ADAM17)-dependent ectodomain shedding, in particular of epidermal growth factor receptor (EGFR) ligands and of the type 1 inflammatory cytokine tumor necrosis factor (TNF), reduces pro-inflammatory and pro-fibrotic responses after ischemic AKI or unilateral ureteral obstruction (UUO), a classical fibrosis model.
Subclinical cognitive impairment in chronic kidney disease is associated with frailty and reduced quality of life
Robin Greinert, Daniel Greinert, Anna-Lena Eger, Cristina Ripoll, Matthias Girndt
doi : 10.1093/ndt/gfac303
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1151–1157
Cognitive impairment (CI) in chronic kidney disease (CKD) is highly prevalent and is associated with multiple limitations to patients as well as a higher mortality, more days of hospitalisation and a lower quality of life. Frailty in CKD is associated with adverse health outcomes and is also highly prevalent. The aim of our study was to determine the prevalence and characteristics of CI and relate the findings to frailty, mobility, muscle strength and health-related quality of life (HRQOL).
Validity and reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS®) using computerized adaptive testing in patients with advanced chronic kidney disease
Esmee M van der Willik, Fenna van Breda, Brigit C van Jaarsveld, Marlon van de Putte, Isabelle W Jetten, Friedo W Dekker, Yvette Meuleman, Frans J van Ittersum, Caroline B Terwee
doi : 10.1093/ndt/gfac231
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1158–1169
The Patient-Reported Outcomes Measurement Information System (PROMIS®) has been recommended for computerized adaptive testing (CAT) of health-related quality of life. This study compared the content, validity, and reliability of seven PROMIS CATs to the 12-item Short-Form Health Survey (SF-12) in patients with advanced chronic kidney disease.
Care processes and outcomes of deprivation across the clinical course of kidney disease: findings from a high-income country with universal healthcare
Simon Sawhney, Tom Blakeman, Dimitra Blana, Dwayne Boyers, Nick Fluck, Mintu Nath, Shona Methven, Magdalena Rzewuska, Corri Black
doi : 10.1093/ndt/gfac224
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1170–1182
No single study contrasts the extent and consequences of inequity of kidney care across the clinical course of kidney disease.
Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up
Yngvar Lunde Haaskjold, Njål Gjærde Lura, Rune Bjørneklett, Leif Bostad, Lars Sigurd Bostad, Thomas Knoop
doi : 10.1093/ndt/gfac225
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1183–1191,
Recently, two immunoglobulin A (IgA) nephropathy-prediction tools were developed that combine clinical and histopathologic parameters. The International IgAN Prediction Tool predicts the risk for 50% declines in the estimated glomerular filtration rate or end-stage kidney disease up to 80 months after diagnosis.
Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis
Clément Samoreau, Giorgina Barbara Piccoli, Cécile Martin, Philippe Gatault, Emeline Vinatier, Frank Bridoux, Jérémie Riou, Alice Desouche, Pierre Jourdain, Jean-Philippe Coindre, Samuel Wacrenier, Fanny Guibert, Nicolas Henry, Odile Blanchet, Anne Croué, Assia Djema, Lise-Marie Pouteau, Marie-Christine Copin, Céline Beauvillain, Jean-François Subra, Jean-François Augusto, Benoit Brilland
doi : 10.1093/ndt/gfac240
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1192–1203
Anti-neutrophil cytoplasmic antibody (ANCA) kinetic in ANCA-associated vasculitis with glomerulonephritis (AAV-GN) has been suggested to be associated with AAV relapse. Few studies have focused on its association with renal prognosis. Thus we aimed to investigate the relationship between ANCA specificity and the evolutive profile and renal outcomes.
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
Masaomi Nangaku, Hirotaka Takama, Tomohiro Ichikawa, Kazuya Mukai, Masahiro Kojima, Yusuke Suzuki, Hirotaka Watada, Takashi Wada, Kohjiro Ueki, Ichiei Narita, Naoki Kashihara, Takashi Kadowaki, Hiroki Hase, Tadao Akizawa
doi : 10.1093/ndt/gfac242
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1204–1216
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD), but currently available treatments do not improve kidney function or prevent the initiation of dialysis/kidney replacement therapy.
Thrombotic microangiopathy in patients with malignant hypertension
Teresa Cavero, Pilar Auñón, Fernando Caravaca-Fontán, Hernando Trujillo, Emi Arjona, Enrique Morales, Elena Guillén, Miquel Blasco, Cristina Rabasco, Mario Espinosa, Marta Blanco, Catuxa RodrÃguez-Magariños, Mercedes Cao, Ana Ã�vila, Ana Huerta, Esther Rubio, Virginia Cabello, Xoana Barros, Elena Goicoechea de Jorge, Santiago RodrÃguez de Córdoba, Manuel Praga on behalf of the Spanish Group for the Study of Glomerular Diseases
doi : 10.1093/ndt/gfac248
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1217–1226
Thrombotic microangiopathy (TMA) is a complication of malignant hypertension (mHTN) attributed to high blood pressure (BP). However, no studies have investigated in patients with mHTN of different aetiologies whether the presence of TMA is associated with specific causes of mHTN.
Coronary and extra-coronary artery calcium scores as predictors of cardiovascular events and mortality in chronic kidney disease stages 1–5: a prospective cohort study
Ida M H Sørensen, Sasha S Bjergfelt, Henrik Ø Hjortkjær, Klaus F Kofoed, Theis Lange, Bo Feldt-Rasmussen, Christina Christoffersen, Susanne Bro
doi : 10.1093/ndt/gfac252
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1227–1239
Vascular calcification is a known risk factor for cardiovascular events and mortality in patients with chronic kidney disease (CKD). However, since there is a lack of studies examining several arterial regions at a time, we aimed to evaluate the risk of major adverse cardiovascular events (MACE) and all-cause mortality according to calcium scores in five major arterial sites.
Association between the fatty liver index and chronic kidney disease: the population-based KORA study
Xinting Cai, Barbara Thorand, Simon Hohenester, Wolfgang Koenig, Wolfgang Rathmann, Annette Peters, Jana Nano
doi : 10.1093/ndt/gfac266
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1240–1248
We aimed to evaluate the relationship of fatty liver, estimated by the fatty liver index (FLI), with kidney function and chronic kidney disease (CKD) in a German cohort study, given the lack of prospective evidence in Europeans.
Impact of a continuous quality improvement program on contrast-induced nephropathy in outpatients with chronic kidney disease: an interrupted time-series study
Keita Hirano, Daiki Kobayashi, Takuro Shimbo, Yasuhiro Komatsu
doi : 10.1093/ndt/gfac268
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1249–1259
Contrast-induced nephropathy (CIN) caused by exposure to radioactive contrast media can cause acute kidney injury in patients with chronic kidney disease (CKD).
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
Phil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, C David Sjöström, Bergur Stefansson, Stephen Nolan, Ricardo Correa-Rotter, Peter Rossing, Glenn M Chertow, John J V McMurray, David C Wheeler, Hiddo J L Heerspink
doi : 10.1093/ndt/gfac280
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1260–1270
The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was terminated prematurely due to overwhelming efficacy. The study objective was to model the long-term clinical outcomes of DAPA-CKD beyond the trial follow-up.
Microbiology and outcomes of polymicrobial peritonitis associated with peritoneal dialysis: a register-based cohort study from the French Language Peritoneal Dialysis Registry
Valentine Forté, Sophie Novelli, Mohamad Zaidan, Renaud Snanoudj, Christian Verger, Séverine Beaudreuil
doi : 10.1093/ndt/gfac267
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1271–1281
Previous studies have reported that polymicrobial peritonitis in peritoneal dialysis (PD) is associated with poor outcomes, but recent data from European cohorts are scarce.
Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
Ursula Thiem, Tim D Hewitson, Nigel D Toussaint, Stephen G Holt, Maria C Haller, Andreas Pasch, Daniel Cejka, Edward R Smith
doi : 10.1093/ndt/gfac271
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1282–1296
Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy with sucroferric oxyhydroxide (SO) would reduce endogenous CPP levels and attenuate pro-calcific and pro-inflammatory effects of patient serum towards human vascular cells in vitro.
Self-reported health change in haemodialysis recipients modulates the effect of frailty upon mortality and hospital admissions: outcomes from a large prospective UK cohort
Benjamin M Anderson, Muhammad Qasim, Gonzalo Correa, Felicity Evison, Suzy Gallier, Charles J Ferro, Thomas A Jackson, Adnan Sharif
doi : 10.1093/ndt/gfac287
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1297–1308,
Frailty among haemodialysis patients is associated with hospitalization and mortality, but high frailty prevalence suggests further discrimination of risk is required. We hypothesized that incorporation of self-reported health with frailty measurement may aid risk stratification.
Glycated albumin to glycated hemoglobin ratio and mortality in diabetic patients on dialysis: a new association
Junichi Hoshino, Masanori Abe, Takayuki Hamano, Takeshi Hasegawa, Atsushi Wada, Shigeru Nakai, Norio Hanafusa, Ikuto Masakane, Kosaku Nitta
doi : 10.1093/ndt/gfac297
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1309–1317
Hemoglobin A1c (A1c) and glycated albumin (GA) are two blood glycated proteins commonly used to monitor glycemic control in dialysis patients with diabetes. However, little is known about the association between the GA/A1c ratio and mortality in these populations. Here, we examine these associations using a nationwide cohort.
Two-step screening for depressive symptoms in patients treated with kidney replacement therapies: a cross-sectional analysis
Sumaya Dano, Haoyue Helena Lan, Sara Macanovic, Susan Bartlett, Doris Howell, Madeline Li, Janel Hanmer, John Devin Peipert, Marta Novak, Istvan Mucsi
doi : 10.1093/ndt/gfac262
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1318–1326
Systematic screening for depressive symptoms may identify patients who may benefit from clinical assessment and psychosocial support. Here we assess a two-step screening using ultrabrief pre-screeners [Edmonton Symptom Assessment Survey–revised Depression item (ESASr-D) or Patient Health Questionnaire-2 (PHQ-2)] followed by the Patient-Reported Outcomes Measurement Information System Depression questionnaire (PROMIS-D) to identify depressive symptoms in patients on kidney replacement therapies.
Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score–matched cohort study
Safak Mirioglu, Ahmet Burak Dirim, Murat Bektas, Erol Demir, Yavuz Burak Tor, Yasemin Ozluk, Isin Kilicaslan, Ozgur Akin Oto, Yasemin Yalcinkaya, Yasar Caliskan, Bahar Artim-Esen, Halil Yazici, Murat Inanc, Aydin Turkmen, Ahmet Gul, Mehmet Sukru Sever
doi : 10.1093/ndt/gfac335
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1327–1336
Data on use of interleukin (IL)-1 blockers in kidney transplant recipients (KTRs) with familial Mediterranean fever (FMF) are very limited. We aimed to evaluate the efficacy and safety of anakinra and canakinumab in the transplantation setting.
Association of environmental lead toxicity and hematologic outcomes in patients with advanced kidney disease
Subhash Paudel, Parvathy Geetha, Periklis Kyriazis, Aaron Specht, Howard Hu, John Danziger
doi : 10.1093/ndt/gfac336
Nephrology Dialysis Transplantation, Volume 38, Issue 5, May 2023, Pages 1337–1339
